Rockwell Medical (NASDAQ:RMTI) Issues Earnings Results

Rockwell Medical (NASDAQ:RMTI) announced its quarterly earnings results on Thursday. The company reported ($0.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.41), Zacks reports. Rockwell Medical had a negative net margin of 7.33% and a negative return on equity of 14.03%. The business had revenue of $19.12 million during the quarter, compared to analysts’ expectations of $18.22 million.

Here are the key takeaways from Rockwell Medical’s conference call:

• Third-quarter net sales rose 20% to $19.1 million, driven by new customers and larger orders from existing customers, including the five largest U.S. dialysis providers. Gross profit increased 37% and gross margin improved to 16% from 14% a year earlier.
• Rockwell agreed to acquire Vantive’s global hemodialysis business, adding machines, water-treatment systems, consumables, services, and manufacturing capacity. The company estimates the combined business could generate $400 million to $450 million in annual revenue, with about 90% recurring, but the transaction remains subject to approvals and is expected to close in mid-2027.
• The company reported a third-quarter net loss of $2.3 million and adjusted EBITDA of negative $300,000; cash, cash equivalents, and available-for-sale investments declined to $22.5 million from $24.8 million at the end of the prior quarter. Higher freight, material, and supply costs also weighed on gross margin.
• Rockwell withdrew its full-year 2026 guidance, citing the pending Vantive acquisition and related expenses. Management said it expects to provide full-company guidance around March, after the Form 10-K is released.

Rockwell Medical Price Performance

RMTI stock traded down $0.43 during trading on Friday, hitting $6.95. The stock had a trading volume of 11,837 shares, compared to its average volume of 40,789. The company’s 50 day moving average price is $7.82 and its two-hundred day moving average price is $8.10. Rockwell Medical has a 1-year low of $4.89 and a 1-year high of $12.90. The stock has a market cap of $28.01 million, a price-to-earnings ratio of -5.19 and a beta of 1.75. The company has a debt-to-equity ratio of 0.21, a quick ratio of 3.00 and a current ratio of 3.25.

Key Rockwell Medical News

These are some of the RMTI news items that stood out recently:

• Positive Sentiment: Rockwell said the combined company could generate $400 million to $450 million in annual revenue after acquiring Vantive’s hemodialysis-related business. The company is targeting a mid-2027 closing. Combined revenue outlook and Vantive timing
• Negative Sentiment: The quarterly loss was $0.59 per share, far wider than the $0.18 loss analysts expected, and the net loss expanded to $2.3 million from $1.8 million a year earlier. The earnings miss could offset the revenue and margin gains. Rockwell Medical Q3 results
• Negative Sentiment: Regulatory approvals for the Vantive transaction could come with costly conditions and weaken expected synergies, creating uncertainty around the deal’s economics and execution. Regulatory risks for the Vantive deal

Analysts Set New Price Targets

RMTI has been the subject of a number of recent research reports. Weiss Ratings raised shares of Rockwell Medical from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, October 8th. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 target price on shares of Rockwell Medical in a research note on Friday, September 11th. Zacks Research cut Rockwell Medical from a “hold” rating to a “strong sell” rating in a report on Wednesday, October 14th. Finally, Wall Street Zen upgraded Rockwell Medical to a “hold” rating in a report on Saturday, July 25th. One investment analyst has rated the stock with a Buy rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Reduce” and a consensus price target of $20.00.

Rockwell Medical Company Profile

Rockwell Medical, Inc. is a healthcare company focused on developing, manufacturing and commercializing products used in the treatment of patients with end-stage renal disease (ESRD) who receive hemodialysis. The company supplies products intended to support anemia management and other aspects of dialysis care. Its principal pharmaceutical product is Triferic, an iron replacement therapy designed to deliver iron to hemodialysis patients through the dialysate. Rockwell Medical also markets Triferic AVNU, an intravenous formulation administered during hemodialysis.